Serum chemerin and vaspin in non-alcoholic fatty liver disease

References

• Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444:847–53.
   PubMed Web of Science ®Google Scholar
• Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821–30.
   PubMed Web of Science ®Google Scholar
• Bozaoglu K, Bolton K, McMillan J, McMillan J, Zimmet P, Jowett J, Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148:4687–94.
   PubMed Web of Science ®Google Scholar
• Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC. A novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282:28175–88.
   PubMed Web of Science ®Google Scholar
• Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ 2008;15:226–33.
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Oppenheim JJ. Chemerin reveals a chimeric nature. JEM 2008;205:2187–90.
   Google Scholar
• Cash JL, Hart R, Russ A, Dixon JPC, Colledge WH, Doran J, Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med 2008;205:767–75.
   PubMed Web of Science ®Google Scholar
• Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008;14:741–51.
   PubMed Web of Science ®Google Scholar
• Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006;339:430–6.
   PubMed Web of Science ®Google Scholar
• Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 2008;17:327–33.
   PubMed Web of Science ®Google Scholar
• Gabriel A, Kukla M, Ziolkowski A. Histopathological features and current scoring systems for semiquantitative assessment of nonalcoholic fatty liver disease. Exp Clin Hep 2008;4:RA48–54.
   Google Scholar
• Kukla M, Zwirska-Korczala K, Gabriel A, Ziolkowski A, Wylezol M, Berdowska A, Liver tissue alterations in morbidly obese patients undergoing bariatric surgery. Exp Clin Hep 2007;3:OR12–18.
   Google Scholar
• Ziolkowski A, Wylezol M, Kukla M, Zwirska-Korczala K, Berdowska A, Paredela M, The comparison of scoring scales for liver biopsy assessment in morbidly obese patients undergoing bariatric surgery. Obes Surg 2005;15:1309–14.
   PubMedGoogle Scholar
• Day C, James O. Steatohepatitis: a tale of two “hits”. Gastroenterology 1998;114:842–5.
   PubMed Web of Science ®Google Scholar
• Carter-Kent C, Zein NN, Feldstein AE. Cytokine in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 2008;103:1036–42.
   PubMed Web of Science ®Google Scholar
• Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008;15:91–101.
   PubMedGoogle Scholar
• Williams AL, Hoofangle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95:734–9.
   PubMed Web of Science ®Google Scholar
• Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–26.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, Behling MJ, Contos MJ, Cummings OW, Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–21.
   PubMed Web of Science ®Google Scholar
• Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-a or adiponectin? Hepatology 2004;40:46–54.
   PubMed Web of Science ®Google Scholar
• Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M, Chemerin–a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 2007;362:1013–18.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, Kitzawa R, Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008;582:573–8.
   PubMed Web of Science ®Google Scholar
• Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population–a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152:217–21.
   PubMed Web of Science ®Google Scholar
• Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Visceral adipose tissue derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102:10610–15.
   PubMed Web of Science ®Google Scholar
• Youn BS, Klöting N, Kratzsch J, Lee N, Park JW, Song ES, Serum vaspin concentration in human obesity and type 2 diabetes. Diabetes 2008;57:372–7.
   PubMed Web of Science ®Google Scholar
• Seeger J, Ziegelmeier M, Bachmann A, Lössner U, Kratzsch J, Blüher M, Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008;93:247–51.
   PubMed Web of Science ®Google Scholar
• Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103–7.
   PubMed Web of Science ®Google Scholar
• Powell EE, Cooskley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history on nonalcoholic steatohepatitis: a follow-up study of forty two patients for up to 21 years. Hepatology 1990;11:74–80.
   PubMed Web of Science ®Google Scholar
• Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J, Handel TM, Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 2005;280:34661–6.
   PubMed Web of Science ®Google Scholar
• Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 2009;Jun 24 [Epub ahead of print].
   Google Scholar
• Tan BK, Chen J, Farhatullah S, Adya R, Kaur J, Heutling D, Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009;58:1971–7.
   PubMed Web of Science ®Google Scholar